Sociedad Americana de Hirudoterapia

Leech therapy for postherpetic neuralgia: a single-blind pilot trial

Mueller IM, Stange R, Michalsen A (2012) · Schmerz (Berlin, Germany) · n=28

RCT evidence detailTrial reference
GRADE LowCohort / case series

Study Profile

Design
single-center, single-blind (outcome assessor) pilot RCT (Berlin)
Sample size (n)
28
Intervention
Single session of 3-5 Hirudo medicinalis leeches along the affected dermatome
Comparator
Topical capsaicin 0.075% cream applied 4 times daily for 28 days
Primary endpoint
Brief Pain Inventory (BPI) at day 28
Primary result
BPI pain score reduction 3.4 points in leech vs 1.6 in capsaicin at day 28 (between-group difference 1.8, p=0.04)
Effect size (Cohen's d)
0.68
Follow-up duration
8 weeks

Key Findings

  • Outcome assessor blinded — improves on the typical open-label design
  • Modest effect size (Cohen's d ≈ 0.68) consistent with refractory chronic pain context
  • Tolerability favored leech — capsaicin caused burning sensation in 80% of users
  • Effect sustained through 8 weeks
  • First RCT data for hirudotherapy in a primarily neuropathic pain condition

Limitations

  • Small sample (n=28)
  • Single-blind only — clinician unblinded
  • Single center
  • Postherpetic neuralgia has notoriously high placebo response — single comparison may not control adequately
  • No mechanistic biomarkers

Clinical Implications

Mueller 2012 is the only RCT data for hirudotherapy in a primarily neuropathic pain syndrome. The single-blind design is a methodological improvement on the German naturopathy series. For clinicians, the trial suggests cautious consideration in postherpetic neuralgia patients who have failed first-line treatments (gabapentin, pregabalin, tricyclic antidepressants). The evidence base remains limited and further trials are warranted.

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.